Innovative technologies to improve
drug-candidate selection and clinical-trial design.
SAN
JOSE, Calif., July 30,
2024 /PRNewswire/ -- Verseon and NeuTherX are
pleased to announce their partnership to accelerate drug
development through the use of NeuTherX's scalable organoid
development technology.
Verseon continues to streamline every aspect of creating
medicines that will improve how the world treats all major human
diseases. Characterizing the behavior of drugs in humans has
historically required extensive clinical trials, which entail
considerable time and cost.
Any lab-derived early insight into how drugs will behave
in human patients can make drug trials vastly more efficient. To
that end, Verseon has been developing organoid-based technology to
characterize drugs. Organoids are artificially grown masses of
cells that resemble the function of specific human organs. Testing
drugs on organoids can deliver valuable information on the
potential effects of drugs in real patients before any human is
dosed.
While Verseon continues to internally develop its
groundbreaking suite of technologies for drug development, it also
seeks out partners whose innovations complement its own.
NeuTherX has created methods to rapidly cultivate
organoids at scale. While the company has so far focused on
psychiatric drug development, their expertise lends itself to the
development of a wide range of organoids for other
indications.
Through this new partnership, NeuTherX's technology will
augment Verseon's drug development process.
"Verseon's platform continues to produce a steady stream
of novel drug candidates," said Verseon's CEO Adityo Prakash. "We always strive to better
characterize their potential behavior in human patients and in the
process inform patient selection and improve overall trial design.
NeuTherX's technology will be an excellent addition to our
platform."
NeuTherX's CEO Richard
Hoopes added, "We envision organoid-based testing as the
future of drug candidate selection. We are excited to partner with
Verseon as they apply our technology across the whole spectrum of
human diseases."
ABOUT VERSEON
Verseon International Corporation
(www.verseon.com) is transforming the
delay, prevention, and treatment of disease. Using its Deep Quantum
Modeling + AI platform, Verseon is rolling out a steady stream of
life-changing medicines. Each of the company's drug programs
features multiple novel candidates with unique therapeutic
properties. None of these candidates can be found by other current
methods. Verseon's fast-growing pipeline addresses major human
diseases in the areas of cardiometabolic disorders and cancers. The
company's supporters and advisors include multiple Nobel laureates,
former heads of R&D of major pharmaceutical companies, and
various key opinion leaders in medicine.
ABOUT NEUTHERX
NeuTherX (www.neutherx.com) is
pioneering personalized treatments for neuropsychiatric disorders
using patient-derived brain organoids. Our innovative platform
models each patient's brain biology from somatic cells to develop
precise therapies. By integrating vast data from deep biological
analyses and advanced AI, we extract unique disease signatures for
targeted drug selection and accelerated drug discovery. This
approach aims to overcome the high failure rates of current
treatments, providing effective, personalized solutions and
enhancing clinical trials to deliver innovative therapies
swiftly.
Media Contact
Walter
Jones
381058@email4pr.com
(510) 225-9000
View original
content:https://www.prnewswire.com/news-releases/verseon-and-neutherx-announce-partnership-to-enhance-drug-development-302209348.html
SOURCE Verseon International Corporation & NeuTherX